Log In
BCIQ
Print this Print this
 

Myeloma Prognostic Risk Signature (MyPRS) test

  Manage Alerts
Collapse Summary General Information
Company Signal Genetics Inc.
DescriptionMicroarray-based gene expression profiling assay used to predict low- or high-level risk of early relapse in patients with multiple myeloma (MM)
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics: Personal genomics testing
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsPredict low- or high-level risk of early relapse in patients with multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
Get a free BioCentury trial today